For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.
Adverse Events Module path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Groups
Study -> Results Section -> Adverse Events Module -> Serious Events
Study -> Results Section -> Adverse Events Module -> Other Events
| Title | Description | Deaths # Affected | Deaths # At Risk | Serious # Affected | Serious # At Risk | Other # Affected | Other # At Risk | View |
|---|---|---|---|---|---|---|---|---|
| Arm I | Patients receive oral varenicline once daily on days 1-3 and twice daily thereafter for a total of 6 months or when a comfortable level of smoking abstinence is reached. varenicline: Given orally | None | None | 4 | 137 | 0 | 137 | View |
| Arm II | Patients receive oral varenicline placebo once daily on days 1-3 and twice daily thereafter for a total of 6 months or when a comfortable level of smoking abstinence is reached. placebo: Given orally | None | None | 2 | 45 | 0 | 45 | View |
| Arm III | Patients receive a nicotine patch, with doses tapering over time for a total of 26 weeks. Patients also receive nicotine gum to quell breakthrough urges. Patients may stop treatment when a comfortable level of smoking abstinence is reached. nicotine: Given transdermally and orally | None | None | 2 | 133 | 0 | 133 | View |
| Term | Type | Organ System | Vocab | View |
|---|---|---|---|---|
| Neurobehavioral Adverse Effects | None | Psychiatric disorders | None | View |
| Neurobehavioral Adverse Events | None | Psychiatric disorders | None | View |
| Participant Death | None | General disorders | None | View |
| Heart Attack | None | Cardiac disorders | None | View |
| Skin Rash | None | Skin and subcutaneous tissue disorders | None | View |